Following the succession plan initiated more than a year ago, when Eduardo Sanchiz expressed his wish to devote more time to his family and other interests, the board of directors of Spain’s largest pharma firm Almirall has approved the appointment of Peter Guenter as chief executive effective October 1, 2017.
Mr Guenter joins Almirall from French pharma major Sanofi, where he has worked for the last 22 years, most recently as executive vice president diabetes and cardiovascular global business unit. During his tenure at Sanofi, he held many senior positions including VP Eastern Europe and Northern Europe, VP business management. Before joining Sanofi, he held different positions in sales and marketing at Smith Kline and Ciba Geigy.
“I am particularly satisfied that we have been able to attract Peter Guenter to Almirall. He is a truly global leader and brings a wealth of experience in US, Europe and Emerging Markets. I am convinced he will bring what is needed to develop Almirall to the next level,” said Jorge Gallardo, chairman of Almirall.
“I am excited and eager to join Almirall as CEO. The company has a clearly defined and sound strategy and has the determination and means to execute this strategy, putting the patients and customers at the center of everything we do. Together with my team, I am convinced we will be able to fully unlock the value of Almirall,” said Mr Guenter.
Eduardo Sanchiz has been with Almirall for 13 years and was appointed CEO in July 2011. He will transition with Mr Guenter during the month of September.
Source: The Pharma Letter
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.